Opinion on Drug Delivery in South and Central America

Published within

« | 1 | 2 | » »|

Type Product title / description Pub Price
Expert View
Expert View

AstraZeneca and Boehringer Ingelheim steal limelight at European Society of Cardiology meeting

Well crafted, positive results for AstraZeneca's Brilinta and an unexpected coup for Boehringer Ingelheim's Pradaxa dominated the headlines following this year's European Society of Cardiology's Annual Meeting in Barcelona. Both announcements have a number of important implications for the wider cardiology market, from both therapeutic and commercial perspectives.

Published By Datamonitor
03 Sep 2009
Expert View
Expert View

Battle for HIV drug market share getting fiercer

The HIV market, worth $9.3 billion in 2007, is expected to grow to $15.1 billion by 2017, driven by the increasing prevalence of HIV worldwide and the longer life expectancy of patients receiving treatment. Despite this growth, the competition is getting tougher across all antiretroviral drug classes, which may cause some of the big players in the HIV market to opt out or be squeezed out.

Published By Datamonitor
24 Sep 2008
ResearchWire
ResearchWire

Biologics: a growing but threatened market

Published By Datamonitor
30 Jun 2006
Expert View
Expert View

Can biologic drugs tackle antibiotic resistance?

Antibody-based products present a novel approach to the treatment and prevention of infections, as an alternative to conventional antibiotics. Several companies are developing such agents for a range of indications, but their cost, complex manufacturing methods and mode of administration are restrictive. A high unmet need and well defined target groups are key to commercial success in this market.

Published By Datamonitor
30 Apr 2008
Expert View
Expert View

Directed molecular evolution: lifecycle management for biologics

Although biologics have an extremely attractive growth rate profile compared to small molecules, the rapid market expansion expected to occur between 2005 and 2010 will not continue at the same rate, due in part to the emergence of biosimilars. Thus, biologics manufacturers need to look at optimizing the lifecycle of their products through directed molecular evolution.

Published By Datamonitor
02 Aug 2006
Expert View
Expert View

Diverse challenges await generics industry

Because of the ever-increasing costs of healthcare provision the world over, many governments are enacting legislation to promote generic prescription in order to keep costs down. With drugs worth $160 billion in sales coming off patent by 2015, it would seem a good time to be in the generics industry. However the generics market is not without challenges.

Published By Datamonitor
07 Jul 2006
ResearchWire
ResearchWire

Global biologics: market opportunity awaits

Published By Datamonitor
13 Apr 2006
CommentWire
CommentWire

HIV drugs: patent disputes escalate

Published By Datamonitor
28 Aug 2001
CommentWire
CommentWire

HIV patents: no solution - yet

While the WTO has not yet made a breakthrough on the issue of patent-free HIV drugs for developing economies, something must be done to alleviate the human and economic cost of the HIV epidemic. Western pharma companies will inevitably lose out - the only question is how well their profit maintenance strategies can cushion the blow.

Published By Datamonitor
22 Oct 2002
Expert View
Expert View

Inhaler devices are still a major hurdle in asthma and COPD treatment

Inhaled drug delivery has major advantages over other methods of administration but inhalers can be difficult to use, and those devices which overcome the problems of the majority of inhalers often lack broad availability across molecules and drug classes. A range of therapies in the same type of device would improve proper use of inhalers, which could have a positive impact on treatment.

Published By Datamonitor
04 Jun 2008

« | 1 | 2 | » »|

No help is available.